Nye substituerte pyridino arylpiperaziner er anvendelige ved behandling av benign prostata hyperplasi

• Main Authors: PROUTY CATHERINE P, MURRAY WILLIAM V, KUO GEE-HONG
• Format: Patent
• Language: Norwegian
• Published: 09.08.2004
• Edition: 7
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Foreliggende oppfinnelse angår en serie av heterocykliske substituerte piperaziner med. formel (I), fremgangsmåter for behandling, farmasøytiske sammensetninger inneholdende dem og intermediater anvendt ved deres fremstilling. Forbindelsene ifølge oppfinnelsen inhiberer selektivt binding til <x-la adrenergisk reseptor, en reseptor som er blitt implisert ved benign prostata hyperplasi. Som sådan er forbindelsene potensielt anvendelige ved behandling av denne sykdommen. This invention relates a to a series of heterocyclic substituted piperazines of Formula Imethods of treatment, pharmaceutical compositions containing them, and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the alpha-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.